OncoCyte Corp expected to post a loss of 12  cents a share - Earnings Preview

Insight Molecular Diagnostics

10/05/2022 03:04

* OncoCyte Corp  OCX.OQ   OCX.O  is expected to show a rise
in
quarterly revenue when it reports  results on May 11. 
    * The Irvine California-based  company is expected to report
 a
99.0% increase in revenue to $2.237 million from $1.12 million a
year ago, according to the mean estimate from 7 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for OncoCyte Corp is
for a
loss of 12 cents per share. For the same quarter last year, the
company reported a loss of 5 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for OncoCyte
Corp is
$4​, above​ its last closing price of $1.10. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.14       -0.13      -0.12     Beat    5.6
 Sep. 30 2021  -0.12       -0.12      -0.15     Missed  -29.3
 Jun. 30 2021  -0.09       -0.10      -0.12     Missed  -20​
 Mar. 31 2021  -0.11       -0.10      -0.05     Beat    50
 ​​Dec.        -0.12       -0.11      -0.09     Beat    18.2
 31 2020                                                
 Sep. 30 2020  -0.10       -0.09      -0.10     Missed  -5.3​
 Jun. 30 2020  -0.11       -0.10      -0.14     Missed  -34.6
 Mar. 31 2020  -0.11       -0.11      -0.13     Missed  -22.6
 This summary was machine generated May 10 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated